Nasal Restrictions



NASAL RESTRICTION & SINUSITIS IS ONE OF THE WORLD’S BIGGEST HEALTH CHALLENGES.

Sinusitis & nasal restriction is one of the most common and significant health care problems in the world.1 In US, approximately 31 million Americans are affected annually – leading to 13 million physician office visits and over 600,000 surgical procedures per year.2,3 Sinusitis-related procedural costs to healthcare systems are estimated at over $8.6 billion annually.4 The condition can significantly impair quality of life, physical and emotional capacity, and day-to-day routine.5

ANTIBIOTICS & SURGICAL INTERVENTION DO NOT WORK CONSISTENTLY – OTHER SOLUTIONS ARE NEEDED.

Treatment poses significant challenges due to variable results and frequency of relapse. Upto 40% of patients experience significant adverse event rates across different antibiotics.7 Growing antibiotic-resistance in bacteria with repeated use, as well as failure rates of surgical interventions mean 30% of patients will not experience any improvement in symptoms or quality of life. 8,9 It is critical to find safe and effective treatments for repeated & long-term use, for prevention and/or alternative treatment modality.1

OUR PHF SOLUTION EASES NASAL RESTRICTION & SIGNIFICANTLY IMPROVES RESPIRATORY FUNCTION, WITHIN 3-4 DAYS.

  • In our research, patients who presented with complaints of frequent nasal obstruction, sinus pressure, nasal discharge, discomfort in nose, headache, and even loss of smell have shown significant improvements with our PHF 3-day regimen.

  • We have found particularly encouraging results and improvements in patients 50 years and older, including patients with chronic respiratory conditions, diabetes, and more.

  • In the several patients who have taken our PHF, none to date have shown recurrence of COVID-19 or other respiratory ailments after completing the 3-day regimen. This significantly improves patient’s quality of life, quickly and effectively.

References:

  • 1 - Taw, Malcolm B et al. “Complementary and integrative treatments: rhinosinusitis.” Otolaryngologic clinics of North America vol. 46,3 (2013): 345-66. doi:10.1016/j.otc.2013.02.002
  • 2- Cherry D.K., Hing E., Woodwell D.A. National Ambulatory Medical Care Survey: 2006 summary. Natl Health Stat Report. 2008;(3):1–29. National Center for Health Statistics.
  • 3- Gliklich R.E., Metson R. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg. 1995;113(1):104–109.
  • 4 - Anand V.K. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl. 2004;193:3–5.
  • 5- Senior B.A., Glaze C., Benninger M.S. Use of the Rhinosinusitis Disability Index (RSDI) in rhinologic disease. Am J Rhinol. 2001;15(1):15–20.
  • 6 - Ahovuo-Saloranta A., Borisenko O.V., Kovanen N. Antibiotics for acute maxillary sinusitis. Cochrane Database Syst Rev. 2008;(2) CD000243. 
  • 7 - Poole M.D. Acute bacterial rhinosinusitis: clinical impact of resistance and susceptibility. Am J Med. 2004;117(Suppl 3A):29S–38S.
  • 8 - Kunin C.M. Resistance to antimicrobial drugs-a worldwide calamity. Ann Intern Med. 1993;118(7):557–561.
  • 9 - Brandsted R., Sindwani R. Impact of depression on disease-specific symptoms and quality of life in patients with chronic rhinosinusitis. Am J Rhinol. 2007;21(1):50–54.
 

Contact Us


Head Office USA
Email: info@alakartbiopharma.com
India
Email: info@alakartbiopharma.com
U.A.E
Email: info@alakartbiopharma.com
Africa
Email: info@alakartbiopharma.com